Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus

NCT00704652 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2015-04-07

No results posted yet for this study

Summary

The purpose of this study is to determine whether systemic administration of darbepoetin alpha results in the progression or regression of diabetic macular edema.

Conditions

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY
  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Ursula Schmidt-Erfurth, Prof. · Departmen of Ophthalmology, Medical Unversity of Vienna

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00704652 on ClinicalTrials.gov